POZZI, Samantha
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.782
EU - Europa 5.751
AS - Asia 5.471
SA - Sud America 887
AF - Africa 202
Continente sconosciuto - Info sul continente non disponibili 184
OC - Oceania 32
Totale 28.309
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.403
GB - Regno Unito 2.084
SG - Singapore 1.560
CN - Cina 1.400
IT - Italia 1.100
HK - Hong Kong 657
BR - Brasile 646
VN - Vietnam 593
DE - Germania 529
SE - Svezia 453
FI - Finlandia 335
BD - Bangladesh 276
FR - Francia 263
RU - Federazione Russa 253
UA - Ucraina 248
CA - Canada 193
TR - Turchia 172
IN - India 163
KR - Corea 126
ID - Indonesia 96
BG - Bulgaria 87
AR - Argentina 75
JP - Giappone 62
IQ - Iraq 61
MA - Marocco 56
IE - Irlanda 53
NL - Olanda 52
MX - Messico 47
ES - Italia 44
PL - Polonia 43
ZA - Sudafrica 42
CO - Colombia 37
PK - Pakistan 37
PH - Filippine 36
EC - Ecuador 33
AE - Emirati Arabi Uniti 30
BE - Belgio 29
SA - Arabia Saudita 27
CL - Cile 26
LT - Lituania 26
MY - Malesia 26
CR - Costa Rica 24
AU - Australia 23
CZ - Repubblica Ceca 23
IL - Israele 19
PY - Paraguay 19
VE - Venezuela 19
AT - Austria 18
EG - Egitto 18
UZ - Uzbekistan 17
PR - Porto Rico 15
CH - Svizzera 13
DO - Repubblica Dominicana 13
IR - Iran 13
TN - Tunisia 13
EE - Estonia 12
GT - Guatemala 12
JO - Giordania 12
KE - Kenya 12
NO - Norvegia 12
SV - El Salvador 12
TT - Trinidad e Tobago 12
UY - Uruguay 12
NI - Nicaragua 11
PE - Perù 11
PT - Portogallo 11
SC - Seychelles 11
JM - Giamaica 10
TW - Taiwan 10
AZ - Azerbaigian 9
GP - Guadalupe 9
HN - Honduras 9
HU - Ungheria 9
KG - Kirghizistan 9
TH - Thailandia 9
CW - ???statistics.table.value.countryCode.CW??? 8
NG - Nigeria 8
NZ - Nuova Zelanda 8
RO - Romania 8
BO - Bolivia 7
BZ - Belize 7
DZ - Algeria 7
DK - Danimarca 6
GH - Ghana 6
GR - Grecia 6
KZ - Kazakistan 6
LB - Libano 6
NP - Nepal 6
TZ - Tanzania 6
BH - Bahrain 5
ET - Etiopia 5
AL - Albania 4
BY - Bielorussia 4
CY - Cipro 4
EU - Europa 4
KH - Cambogia 4
MD - Moldavia 4
OM - Oman 4
RS - Serbia 4
AM - Armenia 3
Totale 28.080
Salva come PNG Salva come JPEG
Città #
Ashburn 2.163
Southend 1.620
Fairfield 1.270
Santa Clara 1.240
Singapore 1.012
Woodbridge 829
Hong Kong 646
Chandler 644
Houston 628
San Jose 628
Ann Arbor 487
Seattle 472
Wilmington 458
Cambridge 450
Council Bluffs 422
Jacksonville 420
Beijing 360
Dearborn 320
Nyköping 307
Hefei 292
London 260
Chicago 258
Helsinki 242
Los Angeles 239
New York 233
Ho Chi Minh City 197
Modena 183
The Dalles 155
Frankfurt am Main 145
Hanoi 140
Milan 135
San Diego 135
Seoul 114
Princeton 107
Buffalo 99
São Paulo 98
Salt Lake City 90
Sofia 84
Izmir 81
Eugene 79
Rome 79
Moscow 76
Shanghai 76
Columbus 75
Munich 73
Lauterbourg 67
Dallas 63
Jakarta 63
Toronto 56
Dublin 50
Phoenix 50
Boardman 46
Bremen 46
Casablanca 45
North Bergen 43
Elk Grove Village 42
Redwood City 42
Tokyo 39
Falls Church 38
Des Moines 37
Atlanta 36
San Francisco 36
Fremont 33
Montreal 33
Orem 32
Warsaw 32
Denver 31
Tampa 31
Da Nang 28
Guangzhou 28
San Giuliano Milanese 28
Chennai 26
Miami 26
Bologna 25
Brooklyn 24
Philadelphia 24
Turku 24
Brussels 23
Boston 22
Baghdad 21
Norwalk 21
Paris 21
Lancaster 20
Washington 20
Rio de Janeiro 19
San José 19
Amsterdam 18
Belo Horizonte 18
Charlotte 18
Dong Ket 18
Haiphong 18
Naples 18
Sterling 18
Dhaka 17
Johannesburg 17
Nanjing 17
Ottawa 17
Manchester 16
Poplar 16
Stockholm 16
Totale 19.773
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 658
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 639
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 575
ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. 570
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 556
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 523
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 489
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 481
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 461
Acquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman's disease: a case report 447
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 423
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 414
Cell-penetrating CaCO3nanocrystals for improved transport of NVP-BEZ235 across membrane barrier in T-cell lymphoma 412
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 410
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 410
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 402
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine 396
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection 393
Activity of BKM120 and BEZ235 against lymphoma cells 391
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 389
A model for predicting the risk of developing mild anemia (MA) in patients with lymphoid malignancy. A study of the Gruppo Italiano Studio Linfomi (GISL) 378
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 377
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells 377
Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. 371
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 370
A concise review of lenalidomide therapy for follicular lymphoma 368
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 357
Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. 354
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 354
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 350
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 341
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 340
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 338
A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) InfectionBlood (ASH Annual Meeting Abstracts), Nov 2008; 112: 3054 333
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 333
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 328
BISPHOSPHONATES (BP) RELATED OSTEONECROSIS OF THE JAW (ONJ): A LONG TERM FOLLOW UP (FU) OF A SERIES OF 35 CASES OBSERVED BY GISL 320
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma 312
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy 310
Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases 309
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 308
Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. 307
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts 302
Bortezomib and plasma cell leukemia 301
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 299
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients 299
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 298
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 293
Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy 289
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. 288
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 283
A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function. 279
A high-affinity fully human anti-IL-6 mAb (OP-R003-1, 1339) for the treatment of Multiple Myeloma 276
Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL. 275
Low-molecular-weight heparin for vertebral artery dissection 272
Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease 267
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. 264
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 263
Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection 261
The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo 261
Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination 256
The therapeutic strategy of HDAC6 inhibitors in lymphoproliferative disease 252
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED FOLLICULAR LYMPHOMAS: LOW TOXICITY AND EXTENDED PROGRESSION FREE SURVIVAL. R1235 Barcelona, Spain. Bone Marrow Transplantation March 2004, Volume 33, Supplement 1 250
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 246
Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time 244
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts 239
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma 239
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting 235
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3 beta 230
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. 229
High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. 227
The role of bisphosphonates in multiple myeloma: Mechanisms, side effects, and the future 221
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice 210
A simple and safe nomogram for the management of oral anticoagulation prior to minor surgery 206
Targeting Bruton's Tyrosine Kinase As a Novel Approach to Inhibit Osteoclast Function in Multiple Myeloma 201
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 197
From Osteoclast Differentiation to Osteonecrosis of the Jaw: Molecular and Clinical Insights 196
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 193
Bisphosphonates and Atypical Femoral Fractures 193
Role of thalidomide in previously untreated patients with multiple myeloma 191
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study 180
Fatty acid synthase is a novel therapeutic target in multiple myeloma. 172
Nonpeghylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity 164
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 159
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 156
Clinical trials of bisphosphonates in multiple myeloma 148
Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: Pathophysiology, clinical presentation, and treatment 146
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study) 143
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3Β activation and RNA polymerase II inhibition 134
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 131
Autologous stem cell transplantation for newly diagnosed follicular lymphomas: low toxicity and extended progression free survival 116
Primary cardiac lymphoma: A case report and review 104
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 57
Totale 28.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 103.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 103.200
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.249 0 0 0 0 40 153 100 95 193 148 314 206
2022/20231.821 197 221 163 192 189 263 44 157 250 14 79 52
2023/20241.410 74 77 70 155 322 98 200 160 23 32 70 129
2024/20253.793 123 50 88 270 819 610 288 195 398 171 332 449
2025/20268.046 431 297 563 962 1.221 617 919 447 800 725 591 473
2026/20272.966 259 614 587 1.188 318 0 0 0 0 0 0 0
Totale 28.309